Citations

Clear

4847 citation(s) found for "Tu, Eric".

Spinal cord evaluation in multiple sclerosis: clinical and radiological associations, present and future
Keegan, B. Mark , Absinta, Martina , Henry, Roland G. , Klawiter, Eric C. , Kolind, Shannon , Krieger, Stephen, Laule, Cornelia , Lincoln, John A. , Papinutto, Nico , Smith, Seth A., Flanagan, E P , Henry, Roland G , Klawiter, Eric C , Laule, Cornelia , Messina, Steven, Traboulsee, Anthony , Keegan, B Mark , Kollind, Shannon H , Cohen-Adad, Julien , Flanagan, Eoin P. , Messina, Steven A. , Oh, Jiwon

Mayo Clinic

Brain Communications | November 6, 2024 | Volume: 6 | Issue: 6 | Pages: No page available

10.1093/braincomms/fcae395 | PMID 39611182 Get It

Abstract Spinal cord disease is important in most people with multiple sclerosis, but assessment remains less emphasized in patient care, basic and clinical research and therapeutic trials. The North American Imaging in Multiple Sclerosis Spinal Cord Interest Group was formed to determine and present the contemporary landscape of multiple sclerosis spinal cord evaluation, further existing and advanced spinal cord imaging techniques, and foster collaborative work. Important themes arose: (i) multiple sclerosis spinal cord lesions (differential diagnosis, association with clinical course); (ii) spinal cord radiological–pathological associations; (iii) ‘critical’ spinal cord lesions; (iv) multiple sclerosis topographical model; (v) spinal cord atrophy; and (vi) automated and special imaging techniques. Distinguishing multiple sclerosis from other myelopathic aetiology is increasingly refined by imaging and serological studies. Post-mortem spinal cord findings and MRI pathological correlative studies demonstrate MRI’s high sensitivity in detecting microstructural demyelination and axonal loss. Spinal leptomeninges include immune inflammatory infiltrates, some in B-cell lymphoid-like structures. ‘Critical’ demyelinating lesions along spinal cord corticospinal tracts are anatomically consistent with and may be disproportionately associated with motor progression. Multiple sclerosis topographical model implicates the spinal cord as an area where threshold impairment associates with multiple sclerosis disability. Progressive spinal cord atrophy and ‘silent’ multiple sclerosis progression may be emerging as an important multiple sclerosis prognostic biomarker. Manual atrophy assessment is complicated by rater bias, while automation (e.g. Spinal Cord Toolbox), and artificial intelligence may reduce this. Collaborative research by the North American Imaging in Multiple Sclerosis and similar groups with experts combining distinct strengths is key to advancing assessment and treatment of people with multiple sclerosis spinal cord disease.
Surgical Predictors of Clinical Outcome 6 Years After Revision ACL Reconstruction
Group, The MARS, Wright, Rick W. , Huston, Laura J. , Haas, Amanda K. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Amendola, Annunziato , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M., Creighton, R. Alexander , Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C., Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCormack, Robert G. , Miller, Bruce S., Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Shea, Kevin G. , Slauterbeck, James R., Smith, Matthew V. , Svoboda, Steven J. , Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Wolcott, Michelle L., York, James J. , Group, The MARS, Pennings, Jacquelyn S. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J. , Brophy, Robert H. , Cox, Charles L. , David, Tal S. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Kaeding, Christopher C. , McAllister, David R. , McCarty, Eric C. , Miller, Bruce S., Owens, Brett D. , Sherman, Orrin H. , Spang, Jeffrey T. , Vidal, Armando F. , Williams, James S. , Wolf, Brian R.

Mayo Clinic

The American Journal of Sports Medicine | November 6, 2024 | Volume: 52 | Issue: 13 | Pages: 3286-3294

10.1177/03635465241288227 | PMID 39503722 Get It

Background: Revision anterior cruciate ligament (ACL) reconstruction has been documented to have inferior outcomes compared with primary ACL reconstruction. The reasons why remain unknown. Purpose: To determine whether surgical factors performed at the time of revision ACL reconstruction can influence a patient’s outcome at 6-year follow-up. Study Design: Cohort study; Level of evidence, 2. Methods: Patients who underwent revision ACL reconstruction were identified and prospectively enrolled between 2006 and 2011. Data collected included baseline patient characteristics, surgical technique and pathology, and a series of validated patient-reported outcome instruments: Knee injury and Osteoarthritis Outcome Score (KOOS), International Knee Documentation Committee (IKDC) subjective form, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Marx activity rating score. Patients were followed up for 6 years and asked to complete the identical set of outcome instruments. Regression analysis was used to control for baseline patient characteristics and surgical variables to assess the surgical risk factors for clinical outcomes 6 years after surgery. Results: A total of 1234 patients were enrolled (716 men, 58%; median age, 26 years), and 6-year follow-up was obtained on 79% of patients (980/1234). Using an interference screw for femoral fixation compared with a cross-pin resulted in significantly better outcomes in 6-year IKDC scores (odds ratio [OR], 2.2; 95% CI, 1.2-3.9; P = .008) and KOOS sports/recreation and quality of life subscale scores (OR range, 2.2-2.7; 95% CI, 1.2-4.8; P < .01). Use of an interference screw compared with a cross-pin resulted in a 2.6 times less likely chance of having a subsequent surgery within 6 years. Use of an interference screw for tibial fixation compared with any combination of tibial fixation techniques resulted in significantly improved scores for IKDC (OR, 1.96; 95% CI, 1.3-2.9; P = .001); KOOS pain, activities of daily living, and sports/recreation subscales (OR range, 1.5-1.6; 95% CI, 1.0-2.4; P < .05); and WOMAC pain and activities of daily living subscales (OR range, 1.5-1.8; 95% CI, 1.0-2.7; P < .05). Use of a transtibial surgical approach compared with an anteromedial portal approach resulted in significantly improved KOOS pain and quality of life subscale scores at 6 years (OR, 1.5; 95% CI, 1.02-2.2; P≤ .04). Conclusion: There are surgical variables at the time of ACL revision that can modify clinical outcomes at 6 years. Opting for a transtibial surgical approach and choosing an interference screw for femoral and tibial fixation improved patients’ odds of having a significantly better 6-year clinical outcome in this cohort.
The Fourth Annual Symposium of the Midwest Aging Consortium
Kim, Jinoh , Buffenstein, Rochelle , Vanegas, Natalia-Del Pilar , Agudelo-Garcia, Paula A., Rojas, Mauricio , Englund, Davis A. , Nunes, Allancer , Kohut, Marian L. , Kothadiya, Siddhant , Bardhan, Rizia , Camell, Christina D. , Sturmlechner, Ines , Lamming, Dudley W. , Leiser, Scott F. , Escorcia, Wilber , Gill, Matthew S. , Helfand, Stephen L., Korm, Sovannarith , Pehar, Mariana , Blaszkiewicz, Magdalena , McGregor, Eric R. , Stilgenbauer, Lukas , Taylor, Alicia , McNeill, Elizabeth M. , Sturmlechner, Ines , Lamming, Dudley W , Anderson, Rozalyn M , Bai, Hua , Englund, Davis A. , Bronikowski, Anne M. , Rosas, Lorena , Mora, Ana Lucia , LeBrasseur, Nathan K. , Robbins, Paul D. , Goronzy, Jörg J. , Yeh, Chung‐Yang , Huang, Shijiao , Taylor, Jackson R. , Gribble, Kristin E. , Townsend, Kristy L. , Anderson, Rozalyn M. , Sadagurski, Marianna , Stoeger, Thomas

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | November 5, 2024 | Volume: 79 | Issue: 11 | Pages: No page available

10.1093/gerona/glae236 | PMID 39498863 Get It

Abstract The Midwest Aging Consortium (MAC) has emerged as a critical collaborative initiative aimed at advancing our understanding of aging and developing strategies to combat the rising prevalence of age-related diseases. Founded in 2019, MAC brings together researchers from various disciplines and institutions across the Midwestern United States to foster interdisciplinary geroscience research. This report summarizes the highlights of the Fourth Annual Symposium of MAC, which was held at Iowa State University in May 2023. The symposium featured presentations on a wide array of topics, including studies on slow-aging animals, cellular senescence and senotherapeutics, the role of the immune system in aging, metabolic changes in aging, neuronal health in aging, and biomarkers for measuring the aging process. Speakers shared findings from studies involving a variety of animals, ranging from commonly used species such as mice, rats, worms, yeast, and fruit flies, to less-common ones like naked mole-rats, painted turtles, and rotifers. MAC continues to emphasize the importance of supporting emerging researchers and fostering a collaborative environment, positioning itself as a leader in aging research. This symposium not only showcased the current state of aging biology research but also highlighted the consortium’s role in training the next generation of scientists dedicated to improving the healthspan and well-being of the aging population.
589 BASECAMP-1 is an efficient pre-screening study that identifies patients with HLA LOH and provides mutational, RNA-Seq, and microbiome data for precision logic-gated CAR T therapeutic trials
Molina, Julian R. , Spencer, Kristen , Grierson, Patrick , Ulrickson, Matthew L. , Morelli, Maria Pia , Dahiya, Saurabh , Go, William Y., Patel, Sandip Pravin , Mardiros, Armen, Tebbets, Jessica , Liechty, Kirstin B., Maloney, David G. , Welch, John P., Hecht, J. Randolph , Simeone, Diane M. , Kirtane, Kedar , Specht, Jennifer M. , Murthy, Hemant S. , Park, Jong Chul , Fakih, Marwan , Davila, Marco L , Maus, Marcela V , Ng, Eric W, Welch, John

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A672-A673

10.1136/jitc-2024-sitc2024.0589 Get It

588 EVEREST-1: initial safety data from a seamless phase 1/2 study of A2B530, a logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH
Grierson, Patrick , Welling, Theodore H., Lim, Kian-Huat, Morelli, Maria Pia , Patel, Sandip Pravin , Ulrickson, Matthew L. , Kundranda, Madappa N. , Vong, Judy, Mitchell, Jasmine , Langeberg, Wendy J., Bretzlaff, William, Nikiforow, Sarah , Mardiros, Armen, Maloney, David G. , Liechty, Kirstin B., Hecht, J. Randolph , Go, William Y., Molina, Julian R. , Punekar, Salman R. , Hazim, Antonious , Simeone, Diane M. , Kirtane, Kedar , Lim, Kian-Huat , Castria, Tiago Biachi De , Maus, Marcela V , Locke, Frederick L. , Ng, Eric W

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A670-A671

10.1136/jitc-2024-sitc2024.0588 Get It

Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study
Flanagan, Kevin C. , Earls, Jon, Hiken, Jeffrey, Wellinghoff, Rachel L., Ponder, Michelle, McLeod, Howard L. , Westra, William H. , Vavinskaya, Vera , Sutton, Leisa , Deichaite, Ida , Macdonald, O. Kenneth, Welaya, Karim, Wade, James L. , Azzi, Georges, Pippas, Andrew W., Slim, Jennifer N. , Bank, Bruce, Sui, Xingwei, Kossman, Steven E., Shenkenberg, Todd D., Alexander, Warren L., Price, Katharine A. , Messina, D. , Glasscock, Jarret , Adkins, Douglas, Ley, Jessica C. , Colevas, Alexander Dimitrios , Cohen, Ezra E.W. , Duncavage, Eric James

Mayo Clinic

Journal for ImmunoTherapy of Cancer | November 3, 2024 | Volume: 12 | Issue: 11 | Pages: e009573

10.1136/jitc-2024-009573 | PMID 39489541 Get It

Background Despite advances in cancer care and detection, >65% of patients with squamous cell cancer of the head and neck (HNSCC) will develop recurrent and/or metastatic disease. The prognosis for these patients is poor with a 5-year overall survival of 39%. Recent treatment advances in immunotherapy, including immune checkpoint inhibitors like pembrolizumab and nivolumab, have resulted in clinical benefit in a subset of patients. There is a critical clinical need to identify patients who benefit from these antiprogrammed cell death protein 1 (anti-PD-1) immune checkpoint inhibitors. Methods Here, we report findings from a multicenter observational study, PREDicting immunotherapy efficacy from Analysis of Pre-treatment Tumor biopsies (PREDAPT), conducted across 17 US healthcare systems. PREDAPT aimed to validate OncoPrism-HNSCC, a clinical biomarker assay predictive of disease control in patients with recurrent or metastatic HNSCC treated with anti-PD-1 immune checkpoint inhibitors as a single agent (monotherapy) and in combination with chemotherapy (chemo-immunotherapy). The test used RNA-sequencing data and machine learning models to score each patient and place them into groups of low, medium, or high. Results The OncoPrism-HNSCC prediction significantly correlated with disease control in both the monotherapy cohort (n=62, p=0.004) and the chemo-immunotherapy cohort (n=50, p=0.01). OncoPrism-HNSCC also significantly predicted progression-free survival in both cohorts (p=0.015 and p=0.037, respectively). OncoPrism-HNSCC had more than threefold higher specificity than programmed death-ligand 1 combined positive score and nearly fourfold higher sensitivity than tumor mutational burden for predicting disease control. Conclusions Here, we demonstrate the clinical validity of the OncoPrism-HNSCC assay in identifying patients with disease control in response to anti-PD-1 immune checkpoint inhibitors. Trial registration number NCT04510129.
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation
Dubois, Bruno , Villain, Nicolas , Schneider, Lon S. , Galasko, Douglas, Kivipelto, Miia , Jessen, Frank , Boada, Merçé , Barkhof, Frederik , Frederiksen, Kristian Steen , Planche, Vincent , Bejanin, Alexandre , Ibáñez, Agustín , Blennow, Kaj , Agronin, Marc , Lopera, Francisco, Delano‐Wood, Lisa , Bombois, Stéphanie , Lévy, Richard, Thambisetty, Madhav , Swantek, Sandra, Newhouse, Paul , Feldman, Howard , Frisoni, Giovanni B. , Bejanin, Alexandre , Barkhof, Frederik , Ibañez, Agustín , Boada, Merce , Feldman, Howard H , Fox, Nick C. , Campbell, Noll L. , Hanseeuw, Bernard , Nordberg, Agneta , Froelich, Lutz , Waldemar, Gunhild , Padovani, Alessandro , Rowe, Christopher Cleon , Cappa, Stefano F. , Caramelli, Paulo , Nitríni, Ricardo , Allegri, Ricardo , Slachevsky, Andrea , Souza, Leonardo Cruz de , Bozoki, Andrea C , Widera, Eric , Ritchie, Craig , Lopera, Francisco, Georges, Jean , Jones, David T. , Lavretsky, Helen , Schott, Jonathan M. , Gatchel, Jennifer R.

Mayo Clinic

JAMA Neurology | November 1, 2024 | Volume: 81 | Issue: 12 | Pages: 1304

10.1001/jamaneurol.2024.3770 | PMID 39483064 Get It

Importance Since 2018, a movement has emerged to define Alzheimer disease (AD) as a purely biological entity based on biomarker findings. The recent revision of the Alzheimer’s Association (AA) criteria for AD furthers this direction. However, concerns about a purely biological definition of AD being applied clinically, the understanding of AD by society at large, and the translation of blood-based biomarkers into clinical practice prompt these International Working Group (IWG) updated recommendations. Objective To consider the revised AA criteria and to offer an alternative definitional view of AD as a clinical-biological construct for clinical use. The recommendations of the 2021 IWG diagnostic criteria are updated for further elaborating at-risk and presymptomatic states. Evidence Review PubMed was searched for articles published between July 1, 2020, and March 1, 2024, using the terms “biomarker” OR “amyloid” OR “tau” OR “neurodegeneration” OR “preclinical” OR “CSF” OR “PET” OR “plasma” AND “Alzheimer’s disease.” The references of relevant articles were also searched. Findings In the new AA diagnostic criteria, AD can be defined clinically as encompassing cognitively normal people having a core 1 AD biomarker. However, recent literature shows that the majority of biomarker-positive cognitively normal individuals will not become symptomatic along a proximate timeline. In the clinical setting, disclosing a diagnosis of AD to cognitively normal people with only core 1 AD biomarkers represents the most problematic implication of a purely biological definition of the disease. Conclusions and Relevance The ultimate aim of the field was to foster effective AD treatments, including preventing symptoms and dementia. The approach of diagnosing AD without a clinical and biological construct would be unwarranted and potentially concerning without a clear knowledge of when or whether symptoms will ever develop. It is recommended that those who are amyloid-positive only and, more generally, most biomarker-positive cognitively normal individuals, should not be labeled as having AD. Rather, they should be considered as being at risk for AD. The expansion of presymptomatic AD is viewed as a better diagnostic construct for those with a specific pattern of biomarkers, indicating that they are proximate to the expression of symptoms in the near future.
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT -Methylated Glioblastoma
Kizilbash, Sani H. , Friday, Bret B., Butowski, Nicholas , Mohile, Nimish, Battiste, James , Campian, Jian , Mashru, Sandeep H., Jaeckle, Kurt A. , O’Brien, Barbara , Kabat, Brian, Laack, Nadia L., Hu, Leland , Kumthekar, Priya , Anderson, S. Keith , Dixon, Jesse G. , Kabat, Brian F, Kaufmann, Timothy, Kizilbash, Sani H , Sarkaria, Jann N. , Ballman, Karla V. , Sulman, Erik P. , Giannini, Caterina , Piccioni, David Eric , Drappatz, Jan , Kaufmann, Timothy J. , Ellingson, Benjamin M. , Galanis, Evanthia

Mayo Clinic

JAMA Oncology | October 31, 2024 | Volume: 10 | Issue: 12 | Pages: 1637

10.1001/jamaoncol.2024.4361 | PMID 39480453 Get It

Importance The prognosis for patients with glioblastoma is poor following standard therapy with surgical resection, radiation, temozolomide, and tumor-treating fields. Objectives To evaluate the combination of veliparib and temozolomide in glioblastoma based on preclinical data demonstrating significant chemosensitizing effects of the polyadenosine diphosphate-ribose polymerase 1/2 inhibitor veliparib when combined with temozolomide. Design, Setting, and Participants Patients with newly diagnosed glioblastoma with MGMT promoter hypermethylation who had completed concomitant radiation and temozolomide were enrolled between December 15, 2014, and December 15, 2018, in this Alliance for Clinical Trials in Oncology trial. The data for this analysis were locked on April 21, 2023. Interventions Patients were randomized and treated with standard adjuvant temozolomide (150-200 mg/m 2 orally, days 1-5) combined with either placebo or veliparib (40 mg orally, twice daily, days 1-7) for 6 cycles. Main Outcomes and Measures The primary end point for the phase 3 portion of the trial was overall survival (OS). Results There were 322 patients randomized during the phase 2 accrual period and an additional 125 patients randomized to complete the phase 3 accrual, for a total of 447 patients in the final phase 3 analysis. The median (range) age for patients was 60 (20-85) years and 190 patients (42.5%) were female. The median OS was 24.8 months (90% CI, 22.6-27.7) for the placebo arm and 28.1 months (90% CI, 24.3-33.3) for the veliparib arm ( P = .17). The difference in survival did not meet the prespecified efficacy end point. However, there was a separation of the survival curves that favored the veliparib arm over 24 to 48 months of follow-up. The experimental combination was well tolerated with an acceptable elevation in grade 3 or 4 hematologic toxic effects. Conclusions and Relevance This trial found that adding veliparib to adjuvant temozolomide did not significantly extend OS in patients with newly diagnosed, MGMT -hypermethylated glioblastoma. Trial Registration ClinicalTrials.gov Identifier: NCT02152982
A Novel Algorithm to Analyze Multi-Frequency Electrocochleography Measurements to Monitor Electrode Placement During Cochlear Implant Surgery
Babajanian, Eric E. , Koka, Kanthaiah , Saoji, Aniket A.

Mayo Clinic

Brain Sciences | October 30, 2024 | Volume: 14 | Issue: 11 | Pages: 1096

10.3390/brainsci14111096 | PMID 39595859 Get It

Objectives: During cochlear implant (CI) electrode placement, single low-frequency (e.g., 500 Hz) cochlear microphonics (CM) measurements are used to monitor hair-cell function and provide feedback to avert insertion trauma. However, it can be difficult to differentiate between trauma and the electrode’s progression through the cochlea when monitored with a single frequency. Multi-frequency CM measurements, while more complex to analyze, can provide more accurate feedback by measuring CM from various locations along the basilar membrane. Methods: A new algorithm was developed to analyze multi-frequency CM tracings by comparing amplitude and phase changes across different test frequencies. The new algorithm was evaluated as to its ability to identify drop-alarm instances with the multi-frequency approach, as compared to single-frequency 500 Hz tracings. Results: The algorithm presented in this manuscript uses the relationship between CM amplitude and phase changes across frequencies to provide real-time feedback during CI electrode placement. The results show that multi-frequency CM tracings raised an alarm only 0.5 times, as compared to 2.8 instances of alarm raised for the single-frequency 500 Hz CM measurements. Conclusions: Multi-frequency CM tracings can help reduce the number of alarms which may be false positives prompting unnecessary electrode manipulations, thereby minimizing the risk of insertion trauma.